

Author Index

BR: Book review
CR: Conference report

A

- Abe, I. and Prestwich, G.D., Development of new cholesterol-lowering drugs 389
Adcock, I. and Matthews, J.G., New drugs for asthma (CR) 395
Al-Obeidi, F. and Ostrem, J.A., Factor Xa inhibitors by classical and combinatorial chemistry 223
Allenby, G., *see* Denyer, J. 323
Auer, M., Moore, K.J., Meyer-Almes, F.J., Guenther, R., Pope, A.J. and Stoeckli, K.A., Fluorescence correlation spectroscopy: lead discovery by miniaturized HTS 457
Austin, A., Passion versus fear as the emotion driving scientists 419

B

- Bacher, J.M. and Ellington, A.D., Nucleic acid selection as a tool for drug discovery 265
Balboni, G., *see* Lazarus, L.H. 284
Banks, M., *see* Denyer, J. 323
Bayle, F.-J., *see* Millet, B. 471
Bertelsen, A.H. and Velculescu, V.E., High-throughput gene expression analysis using SAGE 152
Bohlin, L., Natural Products Isolation (BR) 536
Bottomley, S., Bioinformatics 426
Bottomley, S. and Littlejohn, T., Bioinformatics 525
Boymel, J.L., *see* Marshall, W.S. 34
Bradley, D., Electrical genes 9
Bradley, D., A first for selenium in high blood pressure 51
Bradley, D., Semiconducting malaria drugs 103
Bradley, D., Chiroscience/BMS MMP inhibitor progress 196
Bradley, D., ERT cancer suspect? 200
Bradley, D., Efficacy on the other hand 248
Bradley, D., TB compounds to the rescue after heart attack? 301
Bradley, D., BAF and neonatal brain damage 359
Bradley, D., Alosetron in women – improving gut reactions 402
Bradley, D., Viral intelligence on the Web 442

- Bradley, D., Natural extracts: a new perspective on assessing diversity 489
Bradley, D., Hunting for PPAR ligands 535
Brandt, D.W., The core system model: understanding the impact of reliability on high-throughput screening systems 61
Brayden, D., Fast-track approaches to selecting discovery candidates for full development (CR) 6
Bridges, A.J., Cell signaling: signal transduction and gene transcription 443
Brown, J.R. and Warren, P.V., Antibiotic discovery: is it all in the genes? 564
Bryant, S.D., *see* Lazarus, L.H. 284
Burbaum, J.J., Miniaturization technologies in HTS: how fast, how small, how soon? 313

C

- Calne, D.B., *see* Samii, A. 131
Cargill, J.F. and MacCuish, N.E., Object-relational databases: the next wave in pharmaceutical data management 547
Cavalla, D., Virtuality: the tide floods from the West 529
Celis, J.E., Proteomics: key technology in drug discovery (CR) 193
Coe, D.M., Combinatorial technologies – the 'nuts and bolts' (CR) 48
Coleman, R.S., *Drug-DNA Interaction Protocols* (BR) 249
Cooper, P.S., *see* Lazarus, L.H. 284
Cox, B., *see* Denyer, J. 323

D

- Dalton, C. and Seligmann, B., Combinatorial chemistry consortia for cost-effective drug discovery 1
Davidson, A., Investment status of biopharmaceuticals 391
Denyer, J., Worley, J., Cox, B., Allenby, G. and Banks, M., HTS approaches to voltage-gated ion channel drug discovery 323
Dewdney, J.M. and Smith, R.A.G., Putting a new spin on R&D assets in the pharmaceutical industry 353

- Drews, J., Innovation deficit revisited: reflection on the productivity of pharmaceutical R&D 491
Duffin, S., Simplified characterization of combinatorial libraries 483

E

- Eggenweiler, H.-M., Linkers for solid-phase synthesis of small molecules: coupling and cleavage techniques 552
Eickhoff, H., Microtechnologies and miniaturization (CR) 148
Elgersma, F., Genomics in Japan 393
Ellington, A.D., *see* Bacher, J.M. 265
Enhsen, A., Kramer, W. and Wess, G., Bile acids in drug discovery 409

F

- Favreau, L., *see* Palamanda, J.R. 466
Fenwick, S., All that glitters...? 50
Fenwick, S., Case histories in drug discovery (CR) 101
Fenwick, S., Exploring biodiversity 300
Fenwick, S., Bioprospecting or biopiracy? (CR) 399
Fenwick, S., Contemporary R&D – a virtual reality 435
Fernandes, P.B., Society for Biomolecular Screening – highlights (CR) 7

G

- Gard, P., Imidazol receptors – an enlightening experience 445
Giembycz, M.A., *see* Rogers, D.F. 532
Grausz, J.D., Refining genomics 11
Grausz, J.D., Genomics 90
Grindley, J.N., Success rates for strategic alliances – are they good enough? 145
Guenther, R., *see* Auer, M. 457
Guerrini, R., *see* Lazarus, L.H. 284
Gurwitz, D., Emerging molecular targets 144, 388, 426

H

- Hall, A.G., *see* Kearns, P.R. 113
Hamilton, A.D., *see* Sebti, S.M. 26

- Harrison, W., Changes in scale in automated pharmaceutical research 343
- Hart, T., Lamont, A. and Williams, D., New drug targets in inflammation and immunomodulation 516
- Harvey, A., From demons to darlings: drugs from venoms (CR) 531
- Hayes, D.J., *see* Kolb, A. 333
- Holladay, M.W., Neuronal nicotinic ACh receptor modulators 240
- Holzgrabe, U. and Mohr, K., Allosteric modulators of ligand binding to muscarinic acetylcholine receptors 214
- Horikoshi, H. and Yoshioka, T., Troglitazone – a novel antidiabetic drug for treating insulin resistance 79
- Hruby, D.E., *see* Jones, C.H. 495
- Hughes, D., Applying combinatorial technology to bioseparations 50
- Hughes, D., Nine steps to heaven 358
- Hughes, D., *Emerging Drugs: the Prospects for Improved Medicines* (BR) 360
- Hughes, D., *Global Drug Discovery: Exploiting Technologies to Accelerate Drug Development* (BR) 360
- Hughes, D., New HTS imaging technology deal 438
- Hughes, D., Therapeutic antibodies make a comeback 439
- Hughes, D., Predicting the future for R&D – science or art? 487
- Hunter, P.A., Ketolides – a novel form of macrolide: the way forward? 257
- Hwa, J.J., *see* Strader, C.D. 250
- Hyde-DeRuyscher, R., *see* Kay, B.K. 370
- J**
- James, P. and Papen, R., Nanolitre dispensing – a new innovation in robotic liquid handling 429
- Jones, C.H. and Hruby, D.E., New targets for antibiotic development: biogenesis of surface adherence structures 495
- K**
- Kandil, O., The future of the pharmaceutical industry in the Middle East: challenges, controversies and strategies 95
- Kaplita, P.V., *see* Kolb, A. 333
- Kay, B.K., Kurakin, A.V. and Hyde-DeRuyscher, R., From peptides to drugs via phage display 370
- Kearns, P.R. and Hall, A.G., Glutathione and the response of malignant cells to chemotherapy 113
- Kolb, A., Kaplita, P.V., Hayes, D.J., Park, Y-W., Pernell, C., Major, J.S. and Mathis, G., Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence 333, 431 (correction)
- Kramer, W., *see* Enhsen, A. 409
- Kung Sutherland, M.S., *see* Stein, B. 202
- Kurakin, A.V., *see* Kay, B.K. 370
- L**
- Labaudiniere, R., RPR's approach to high-speed parallel synthesis for lead synthesis 511
- Lajiness, M.S., *see* Van Drie, J.H. 274
- Lamb, P., Tapley, P. and Rosen, J., Biochemical approaches to discovering modulators of the JAK-STAT pathway 122
- Lambkin, R., *see* Oxford, J.S. 448
- Lamont, A., *see* Hart, T. 516
- Lazarus, L.H., Bryant, S.D., Cooper, P.S., Guerrini, R., Balboni, G. and Salvadori, S., Design of δ -opioid peptide antagonists for emerging drug applications 284
- Letwin, S.R., *see* Samii, A. 131
- Li, J., Murray, C.W., Waszkowycz, B. and Young, S.C., Targeted molecular diversity in drug discovery: integration of structure-based design and combinatorial chemistry 105
- Lin, C., *see* Palamanda, J.R. 466
- Littlejohn, T., *see* Bottomley, S. 525
- Lloyd, A., Emerging molecular targets 298, 525
- Lloyd, A., Monitor 43, 89, 141, 189, 239, 295, 350, 386, 423, 480, 522, 561
- Lloyd, A., High-throughput screening 566
- M**
- MacCuish, N.E., *see* Cargil, J.F. 547
- Major, J.S., *see* Kolb, A. 333
- Marshall, W.S. and Boymel, J.L., Oligonucleotide synthesis as a tool in drug discovery research 34
- Mathis, G., *see* Kolb, A. 333
- Matthews, J.G. *see* Adcock, I. 395
- Merritt, A.T., Uptake of new technology in lead optimization for drug discovery 505
- Meyer-Almes, F.J., *see* Auer, M. 457
- Millet, B., Bayle F-J. and Olié, J-P., Prospects for anxiolytic therapy: a reflection from different viewpoints 471
- Mir, K.U., Biochips: from chipped gels to microfluidic CDs (CR) 485
- Mohr, K., *see* Holzgrabe, U. 214
- Moore, K.J., *see* Auer, M. 457
- Murcko, M.A., *see* Walters, W.P. 160
- Murray, C.W., *see* Li, J. 105
- N**
- Nomeir, A.A., *see* Palamanda, J.R. 466
- O**
- Olié, J-P., *see* Millet, B. 471
- Ostrem, J.A., *see* Al-Obeidi, F. 223
- Oxford, J.S. and Lambkin, R., Targeting influenza virus neuraminidase – a new strategy for antiviral therapy 448
- P**
- Palamanda, J.R., Favreau, L., Lin, C. and Nomeir, A.A., Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies 466
- Papen, R., *see* James, P. 429
- Park, Y-W., *see* Kolb, A. 333
- Parker, E.M., *see* Strader, C.D. 250
- Pernell, C., *see* Kolb, A. 333
- Pope, A.J., *see* Auer, M. 457
- Prestwich, G.D., *see* Abe, I. 389
- R**
- Rhodes, S.J. and Smith, R.C., Using the power of developmental biology for drug discovery 361
- Rodan, G.A., *see* Yates, A.J. 69
- Rogers, D.F. and Gienbycz, M.A., Conquering airway inflammation in the 21st century (CR) 532
- Rosen, J., *see* Lamb, P. 122
- Roth, B.D., ACAT inhibitors: evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents 19

S

- Salvadori, S., *see* Lazarus, L.H. 284
- Samii, A., Letwin, S.R. and Calne, D.B., Prospects for new drug treatment in idiopathic parkinsonism 131
- Sebti, S.M. and Hamilton, A.D., New approaches to anticancer drug design based on the inhibition of farnesyltransferase 26
- Seligmann, B., *see* Dalton, C. 1
- Sills, M.A., Future considerations in HTS: the acute effect of chronic dilemmas 304
- Simmons, E.S., Prior art searching in the preparation of pharmaceutical patent applications 52
- Smith, R.A.G., *see* Dewdney, J.M. 353
- Smith, R.C., *see* Rhodes, S.J. 361
- Spence, P., Obtaining value from the human genome: a challenge for the pharmaceutical industry 179
- Stahl, M.T., *see* Walters, W.P. 160
- Stein, B. and Kung Sutherland, M.S., IL-6 as a drug discovery target 202
- Stoeckli, K.A., *see* Auer, M. 457
- Strader, C.D., Hwa, J.J., Van Heek, M. and Parker, E.M., Novel molecular targets for the treatment of obesity 250, 431 (correction)
- Szymkowski, D., *Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors* (BR) 403, 527 (correction)

T

- Tapley, P., *see* Lamb, P. 122
- Terrett, N., Combinatorial chemistry 46, 94, 143, 191, 242, 296, 352, 388, 425, 482, 563
- Terrett, N., *The Combinatorial Index* (BR) 302
- Thorne, M., InfoTech Pharma '98: managing the knowledge (CR) 197
- Town, W., Science on the Web: from chaos to community 243

V

- Van Drie, J.H. and Lajiness, M.S., Approaches to virtual library design 274
- Van Heek, M., *see* Strader, C.D. 250
- Velculescu, V.E., *see* Bertelsen, A.H. 152
- Verpoorte, R., Exploration of nature's chemodiversity: the role of secondary metabolites as leads for drug development 232
- Vetter, D., Miniaturization for drug discovery applications 404

W

- Wallace, R.W., Rational therapeutics 4
- Wallace, R.W., Cancer stops at red light 47
- Wallace, R.W., High-throughput screening 92, 192
- Wallace, R.W., Directed cancer drugs 147
- Wallace, R.W., Diversa and diversity 246
- Wallace, R.W., Genomics 297

- Wallace, R.W., A little too much? Expense versus return in HTS miniaturization 299
- Wallace, R.W., Opportunity not exploitation: valuing the Icelandic genome 355
- Wallace, R.W., Media hype and drug discovery 433
- Walters, W.P., Stahl, M.T. and Murcko, M.A., Virtual screening – an overview 160
- Warhurst, D.C., Ant malarial gallium complex 249
- Warhurst, D.C., Ant malarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance 538
- Warren, P.V., *see* Brown, J.R. 564
- Waszkowycz, B., *see* Li, J. 105
- Weber, L., Evolutionary combinatorial chemistry: application of genetic algorithms 379
- Wentland, M.P., Antigene oligonucleotides 45, 144 (correction)
- Wess, G., *see* Enhsen, A. 409
- Whittaker, M., Drug discovery at IKCOC-7 (CR) 149
- Williams, D., *see* Hart, T. 516
- Wingfield, J., Developing effective assays in HTS (CR) 97
- Worley, J., *see* Denyer, J. 323

Y

- Yates, A.J. and Rodan, G.A., Alendronate and osteoporosis 69
- Yoshioka, T., *see* Horikoshi, H. 79
- Young, S.C., *see* Li, J. 105